🇺🇸 FDA
Patent

US 12428455

Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

granted A61KA61K31/337A61K31/4706

Quick answer

US patent 12428455 (Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells) held by The Regents of the University of California expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/337, A61K31/4706, A61K31/704, A61K38/00